GASTROINTESTINAL INFECTIONS

New Therapeutic Repopulates the Gut Microbiome to Prevent Recurrent C Diff Infection

June 20, 2022

Video

Eric Shaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.

Investigational Microbiome Therapeutic SER-109 Reduces C Difficile Recurrence

June 08, 2022

Article

SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.

Fecal Microbiota Transplant Cost-Effective Treatment for Recurrent C Diff Infection

June 03, 2022

Article

Fecal microbiota transplant was a cost-effective treatment for recurrent C diff infection 90% of the time.

Investigational Therapy SER-109 Prevents Recurrent C Difficile Infection

May 23, 2022

Article

Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of recipients.

FDA Approves 2 Vonoprazan Treatments for Helicobacter Pylori Infection

May 03, 2022

Article

Today, the FDA approved vonoprazan dual and triple therapies, developed by Phathom Pharmaceuticals to treat adults with H. pylori infection.

Continuous Enteral Vancomycin Helpful in Cases of Severe Recurrent CDI

April 13, 2022

Article

In a small retrospective study, 7 of 11 patients experienced clinical improvement.

New Vibrio Bacteria in UK Waters as Sea Temperatures Rise

January 10, 2022

Article

Rising sea temperatures cause Vibrio species, bacteria linked to gastroenteritis, to be identified for the first time in UK waters.

Lower BMI Increased Risk of C Diff Infection in Elderly Pneumonia Patients

January 04, 2022

Article

Underweight elderly pneumonia patients were more likely to contract C difficile infection.

Higher Stool Toxin Concentrations Increase Severity of Clostridioides Difficile Infection

December 08, 2021

Article

For the first time, investigators proved that a higher presence of Clostridioides difficile bacteria and toxins cause a more severe infection.

C Difficile Bacteria Pervasive in Non-Healthcare Settings Worldwide, Found on 45% of Shoe Soles

October 08, 2021

Article

A global study of C. difficile isolates worldwide found a very high prevalence of the bacteria on shoe soles.

Latest News

“Doing Quality Work, With Vigor”: Designing the Next Generation Pneumococcal Vaccine

CDC Identifies Adenovirus Infections in 45% of Acute Hepatitis Cases in Children

CDC on the Meningococcal Disease Outbreak: Gay and Bisexual Men Should Get Vaccinated if Living or Traveling to Florida

Combination bNAbs Therapy Could Eventually Replace Daily ART

View More News